MorphoSys AG (MPSYY.PK) News Headlines

▮ More

Date

Headline

5/27/2020 9:08:30 PM MorphoSys Shareholders Approve All Proposed Resolutions

5/20/2020 9:20:25 PM MorphoSys Announce Validation Of EMA Application For Tafasitamab

5/14/2020 9:47:38 AM MorphoSys : Long-term Data From L-MIND Study Confirms Primary Analysis Results

5/14/2020 9:34:56 AM MorphoSys, Incyte Report Updated Results From Ongoing Phase 2 L-MIND Study

5/6/2020 6:07:31 PM MorphoSys Reports Profit In Q1; Affirms Guidance - Quick Facts

5/6/2020 4:43:21 PM MorphoSys Q1 Basic EPS EUR 6.12 Vs Loss EUR 0.72 Last Year

4/27/2020 5:30:16 PM MorphoSys And I-Mab: First Patient Dosed In Phase 3 Clinical Trial of MOR202/TJ202 In R/r Multiple Myeloma In China

4/21/2020 4:21:22 PM MorphoSys Appoints Roland Wandeler Chief Commercial Officer

4/6/2020 11:32:15 PM MorphoSys Halts Enrollment Of Patients In M-PLACE Study With MOR202

3/18/2020 11:12:15 PM MorphoSys FY19 Loss Widens

3/3/2020 9:03:44 PM MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab

3/2/2020 1:18:03 AM MorphoSys : FDA Accepts BLA On Relapsed/refractory Diffuse Large B Cell Lymphoma

3/2/2020 1:04:39 AM MorphoSys: FDA Accepts Filing Of BLA, Granted Priority Review For Tafasitamab

2/4/2020 4:04:01 PM MorphoSys Initiates Expanded Access Program In U.S. For Tafasitamab

1/13/2020 1:54:23 AM MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

1/13/2020 1:38:40 AM MorphoSys Enters Global Collaboration And Licensing Agreement With Incyte

12/30/2019 8:22:20 AM MorphoSys Announces Submission Of BLA For Tafasitamab In R/r DLBCL To FDA

12/27/2019 10:54:51 PM MorphoSys:First Patient Dosed In Phase 1 Study Of Tafasitamab In Firstline DLBCL

11/11/2019 9:33:26 PM MorphoSys's Partner Presents Results For Bimagrumab In Obesity, Type 2 Diabetes

11/6/2019 4:24:46 PM MorphoSys To Present Number Of Important Updates On Tafasitamab At ASH

Morphosys Ag (MPSYY.PK)